JRCT ID: jRCT2080224545
Registered date:04/02/2019
Basic Information
Recruitment status | completed |
---|---|
Health condition(s) or Problem(s) studied | |
Date of first enrollment | 21/12/2018 |
Target sample size | 105 |
Countries of recruitment | Japan,Asia except Japan,North America,Europe |
Study type | Interventional |
Intervention(s) | investigational material(s) Generic name etc : INN of investigational material : capmatinib Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : spartalizumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Generic name etc : INN of investigational material : Docetaxel Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : |
Outcome(s)
Primary Outcome | safety efficacy |
---|---|
Secondary Outcome | safety efficacy pharmacokinetics pharmacogenomics |
Key inclusion & exclusion criteria
Age minimum | >= 18age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | |
Exclude criteria |
Related Information
Primary Sponsor | |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) | NCT03647488,JapicCTI-194614 |
Contact
Public contact | |
Name | |
Address | |
Telephone | +81-120-003-293 |
Affiliation | |
Scientific contact | |
Name | |
Address | |
Telephone | +81-120-003-293 |
Affiliation |